{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:39:08Z","timestamp":1792712348036,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12333-5","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:48:30Z","timestamp":1784119710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Isoproterenol-induced cardiac hypertrophy: mechanistic insights, environmental stressor and molecular cardioprotection"],"prefix":"10.1007","volume":"53","author":[{"family":"Malya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushboo","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7012-0457","authenticated-orcid":false,"given":"Brij","family":"Bharti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"1","key":"12333_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/biomedicines13010241","volume":"13","author":"V Kumar","year":"2025","unstructured":"Kumar V, Huligowda SH, Umesh LKD, Chakraborty M, Thazeem P, B., Singh AP (2025) Environmental pollutants as emerging concerns for cardiac diseases: A review on their impacts on cardiac health. Biomedicines 13(1):241","journal-title":"Biomedicines"},{"issue":"7","key":"12333_CR2","doi-asserted-by":"publisher","first-page":"e0307467","DOI":"10.1371\/journal.pone.0307467","volume":"19","author":"P Perez-Bonilla","year":"2024","unstructured":"Perez-Bonilla P, LaViolette B, Bhandary B, Ullas S, Chen X, Hirenallur-Shanthappa D (2024) Isoproterenol induced cardiac hypertrophy: A comparison of three doses and two delivery methods in C57BL\/6J mice. PLoS ONE 19(7):e0307467","journal-title":"PLoS ONE"},{"issue":"1","key":"12333_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ame2.12496","volume":"8","author":"L Bader Eddin","year":"2025","unstructured":"Bader Eddin L, Nagoor Meeran MF, Kumar Jha N, Goyal SN, Ojha S (2025) Isoproterenol mechanisms in inducing myocardial fibrosis and its application as an experimental model for the evaluation of therapeutic potential of phytochemicals and pharmaceuticals. Anim Models Experimental Med 8(1):67\u201391","journal-title":"Anim Models Experimental Med"},{"key":"12333_CR4","doi-asserted-by":"crossref","unstructured":"Antar SA, Ashour NA, Marawan ME, Al-Karmalawy AA (2023) Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation. International journal of molecular sciences 24(4):4004","DOI":"10.3390\/ijms24044004"},{"issue":"1","key":"12333_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005344-200501000-00003","volume":"45","author":"R Bos","year":"2005","unstructured":"Bos R, Mougenot N, Findji L, M\u00e9diani O, Vanhoutte PM, Lechat P (2005) Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. J Cardiovasc Pharmacol 45(1):8\u201313","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"12333_CR6","doi-asserted-by":"publisher","first-page":"H2410","DOI":"10.1152\/ajpheart.2001.281.6.H2410","volume":"281","author":"FH Leenen","year":"2001","unstructured":"Leenen FH, White R, Yuan B (2001) Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. Am J Physiol Heart Circ Physiol 281(6):H2410\u2013H2416","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6pt2","key":"12333_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1161\/01.HYP.19.6.708","volume":"19","author":"M Nagano","year":"1992","unstructured":"Nagano M, Higaki J, Nakamura F, Higashimori K, Nagano N, Mikami H, Ogihara T (1992) Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. Hypertension 19(6pt2):708\u2013712","journal-title":"Hypertension"},{"issue":"2","key":"12333_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/00005344-200208000-00010","volume":"40","author":"MP Ocaranza","year":"2002","unstructured":"Ocaranza MP, D\u00edaz-Araya G, Chiong M, Munoz D, Riveros JP, Ebensperger R, Sabat S, Irarr\u00e1zaval P, Jalil JE, Lavandero S (2002) Isoproterenol and angiotensin I-converting enzyme in lung, left ventricle, and plasma during myocardial hypertrophy and fibrosis. J Cardiovasc Pharmacol 40(2):246\u2013254","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"12333_CR9","doi-asserted-by":"publisher","first-page":"H2371","DOI":"10.1152\/ajpheart.01145.2005","volume":"291","author":"LA Campos","year":"2006","unstructured":"Campos LA, Iliescu R, Fontes MA, Schlegel WP, Bader M, Baltatu OC (2006) Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen. Am J Physiol Heart Circ Physiol 291(5):H2371\u2013H2376","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"12333_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1113\/expphysiol.2011.063230","volume":"97","author":"B Mart\u00edn-Fern\u00e1ndez","year":"2012","unstructured":"Mart\u00edn-Fern\u00e1ndez B, de las Heras N, Miana M, Ballesteros S, Valero\u2010Mu\u00f1oz M, Vassallo D, Davel AP, Rossoni LV, Cachofeiro V, Lahera V (2012) Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum\u2010and glucocorticoid\u2010regulated kinase type 1. Exp Physiol 97(6):710\u2013718","journal-title":"Exp Physiol"},{"issue":"4","key":"12333_CR11","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.yjmcc.2007.01.012","volume":"42","author":"GX Zhang","year":"2007","unstructured":"Zhang GX, Ohmori K, Nagai Y, Fujisawa Y, Nishiyama A, Abe Y, Kimura S (2007) Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. J Mol Cell Cardiol 42(4):804\u2013811","journal-title":"J Mol Cell Cardiol"},{"key":"12333_CR12","doi-asserted-by":"publisher","first-page":"120106","DOI":"10.1016\/j.lfs.2021.120106","volume":"287","author":"Y Du","year":"2021","unstructured":"Du Y, Demillard LJ, Ren J (2021) Catecholamine-induced cardiotoxicity: a critical element in the pathophysiology of stroke-induced heart injury. Life Sci 287:120106","journal-title":"Life Sci"},{"issue":"1","key":"12333_CR13","first-page":"1934578X2211445","volume":"18","author":"J Liu","year":"2023","unstructured":"Liu J, Li J, Yang S, She Y, Li X, Jia Y (2023) Phillyrin inhibits isoproterenol-induced cardiac hypertrophy via P38 and NF-\u03baB pathways. Nat Prod Commun 18(1):1934578X221144581","journal-title":"Nat Prod Commun"},{"issue":"3","key":"12333_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12265-023-10472-9","volume":"17","author":"Y Wu","year":"2024","unstructured":"Wu Y, Peng W, Chen S, Zeng X, Zhu J, Zhu P (2024) CAV1 protein encapsulated in mouse BMSC-derived extracellular vesicles alleviates myocardial fibrosis following myocardial infarction by blocking the TGF-\u03b21\/SMAD2\/c-JUN Axis. J Cardiovasc Transl Res 17(3):523\u2013539","journal-title":"J Cardiovasc Transl Res"},{"key":"12333_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12012-019-09548-3","volume":"20","author":"N Nalban","year":"2020","unstructured":"Nalban N, Sangaraju R, Alavala S, Mir SM, Jerald MK, Sistla R (2020) Arbutin attenuates isoproterenol-induced cardiac hypertrophy by inhibiting TLR-4\/NF-\u03baB pathway in mice. Cardiovasc Toxicol 20:235\u2013248","journal-title":"Cardiovasc Toxicol"},{"key":"12333_CR16","doi-asserted-by":"publisher","first-page":"p217818","DOI":"10.3389\/fphar.2016.00392","volume":"7","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Xu J, Long Z, Wang C, Wang L, Sun P, Li P, Wang T (2016) Hydrogen (H2) inhibits isoproterenol-induced cardiac hypertrophy via antioxidative pathways. Front Pharmacol 7:p217818","journal-title":"Front Pharmacol"},{"issue":"5","key":"12333_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3109\/15376516.2012.666650","volume":"22","author":"SK Maulik","year":"2012","unstructured":"Maulik SK, Kumar S (2012) Oxidative stress and cardiac hypertrophy: a review. Toxicol Mech Methods 22(5):359\u2013366","journal-title":"Toxicol Mech Methods"},{"issue":"9","key":"12333_CR18","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/s41401-023-01086-7","volume":"44","author":"Z Guo","year":"2023","unstructured":"Guo Z, Hu YH, Feng GS, Valenzuela Ripoll C, Li ZZ, Cai SD, Wang QQ, Luo WW, Li Q, Liang LY, Wu ZK (2023) JMJD6 protects against isoproterenol-induced cardiac hypertrophy via inhibition of NF-\u03baB activation by demethylating R149 of the p65 subunit. Acta Pharmacol Sin 44(9):1777\u20131789","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"12333_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11010-017-3253-0","volume":"445","author":"N Saleem","year":"2018","unstructured":"Saleem N, Prasad A, Goswami SK (2018) Apocynin prevents isoproterenol-induced cardiac hypertrophy in rat. Mol Cell Biochem 445(1):79\u201388","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"12333_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1479-5876-11-130","volume":"11","author":"D Chowdhury","year":"2013","unstructured":"Chowdhury D, Tangutur AD, Khatua TN, Saxena P (2013) Banerjee, and Manika Pal Bhadra. A proteomic view of isoproterenol induced cardiac hypertrophy: prohibitin identified as a potential biomarker in rats. J translational Med 11(1):130","journal-title":"J translational Med"},{"key":"12333_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3389\/fimmu.2017.00719","volume":"8","author":"PB Katare","year":"2017","unstructured":"Katare PB, Bagul PK, Dinda AK, Banerjee SK (2017) Toll-like receptor 4 inhibition improves oxidative stress and mitochondrial health in isoproterenol-induced cardiac hypertrophy in rats. Front Immunol 8:719","journal-title":"Front Immunol"},{"issue":"10","key":"12333_CR22","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.biocel.2008.02.020","volume":"40","author":"SP Barry","year":"2008","unstructured":"Barry SP, Davidson SM, Townsend PA (2008) Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 40(10):2023\u20132039","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"12333_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1161\/CIRCRESAHA.118.312708","volume":"123","author":"S Dey","year":"2018","unstructured":"Dey S, DeMazumder D, Sidor A, Foster DB, O\u2019Rourke B (2018) Mitochondrial ROS drive sudden cardiac death and chronic proteome remodeling in heart failure. Circul Res 123(3):356\u2013371","journal-title":"Circul Res"},{"issue":"1\u20132","key":"12333_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/03602532.2022.2162075","volume":"55","author":"MA ElKhatib","year":"2023","unstructured":"ElKhatib MA, Isse FA, El-Kadi AO (2023) Effect of inflammation on cytochrome P450-mediated arachidonic acid metabolism and the consequences on cardiac hypertrophy. Drug Metab Rev 55(1\u20132):50\u201374","journal-title":"Drug Metab Rev"},{"issue":"3","key":"12333_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41401-023-01179-3","volume":"45","author":"JF Qian","year":"2024","unstructured":"Qian JF, Liang SQ, Wang QY, Xu JC, Luo W, Huang WJ, Wu GJ, Liang G (2024) Isoproterenol induces MD2 activation by \u03b2-AR-cAMP-PKA-ROS signaling axis in cardiomyocytes and macrophages drives inflammatory heart failure. Acta Pharmacol Sin 45(3):531\u2013544","journal-title":"Acta Pharmacol Sin"},{"issue":"8","key":"12333_CR26","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1124\/dmd.115.063776","volume":"43","author":"HN Althurwi","year":"2015","unstructured":"Althurwi HN, Maayah ZH, Elshenawy OH, El-Kadi AO (2015) Early changes in cytochrome P450s and their associated arachidonic acid metabolites play a crucial role in the initiation of cardiac hypertrophy induced by isoproterenol. Drug Metab Dispos 43(8):1254\u20131266","journal-title":"Drug Metab Dispos"},{"key":"12333_CR27","doi-asserted-by":"crossref","unstructured":"Rihan M, Sharma SS (2024) Compound 3K attenuates isoproterenol-induced cardiac hypertrophy by inhibiting pyruvate kinase M2 (PKM2) pathway. Life Sciences 351:122837","DOI":"10.1016\/j.lfs.2024.122837"},{"issue":"6","key":"12333_CR28","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1161\/01.HYP.0000071180.12012.6E","volume":"41","author":"IL Ennis","year":"2003","unstructured":"Ennis IL, Escudero EM, Console GM, Camihort G, Dumm CG, Seidler RW, de Camili\u00f3n MC, Cingolani HE (2003) Regression of isoproterenol-induced cardiac hypertrophy by Na+\/H+ exchanger inhibition. Hypertension 41(6):1324\u20131329","journal-title":"Hypertension"},{"key":"12333_CR29","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2741\/e484","volume":"4","author":"Y Fu","year":"2012","unstructured":"Fu Y, Xiao H, Zhang Y (2012) Beta-adrenoceptor signaling pathways mediate cardiac pathological remodeling. Front Biosci (Elite Ed) 4:1625\u20131637","journal-title":"Front Biosci (Elite Ed)"},{"issue":"25","key":"12333_CR30","doi-asserted-by":"publisher","first-page":"pe31","DOI":"10.1126\/scisignal.125pe31","volume":"1","author":"SR Houser","year":"2008","unstructured":"Houser SR, Molkentin JD (2008) Does contractile Ca2\u2009+\u2009control calcineurin-NFAT signaling and pathological hypertrophy in cardiac myocytes? Sci Signal 1(25):pe31\u2013pe31","journal-title":"Sci Signal"},{"issue":"8","key":"12333_CR31","doi-asserted-by":"publisher","first-page":"226","DOI":"10.31083\/j.rcm2408226","volume":"24","author":"E Floris","year":"2023","unstructured":"Floris E, Cozzolino C, Marconi S, Tonicello F, Picchio V, Pagano F, Chimenti I (2023) A review of therapeutic strategies against cardiac fibrosis: From classical pharmacology to novel molecular, epigenetic, and biotechnological approaches. Rev Cardiovasc Med 24(8):226","journal-title":"Rev Cardiovasc Med"},{"issue":"4","key":"12333_CR32","first-page":"173","volume":"8","author":"W Zhang","year":"2003","unstructured":"Zhang W, Elimban V, Nijjar MS, Gupta SK, Dhalla NS (2003) Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure. Experimental Clin Cardiol 8(4):173","journal-title":"Experimental Clin Cardiol"},{"issue":"1","key":"12333_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10787-024-01635-4","volume":"33","author":"G Kannan","year":"2025","unstructured":"Kannan G, Paul BM, Thangaraj P (2025) Stimulation, regulation, and inflammaging interventions of natural compounds on nuclear factor kappa B (NF-kB) pathway: a comprehensive review. Inflammopharmacology 33(1):145\u2013162","journal-title":"Inflammopharmacology"},{"key":"12333_CR34","doi-asserted-by":"publisher","first-page":"1529756","DOI":"10.3389\/fimmu.2025.1529756","volume":"16","author":"J Kaszycki","year":"2025","unstructured":"Kaszycki J, Kim M (2025) Epigenetic regulation of transcription factors involved in NLRP3 inflammasome and NF-kB signaling pathways. Front Immunol 16:1529756","journal-title":"Front Immunol"},{"issue":"25","key":"12333_CR35","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.2174\/1381612821666150710150445","volume":"21","author":"A Fukushima","year":"2015","unstructured":"Fukushima A, Milner K, Gupta A, Lopaschuk D, G (2015) Myocardial energy substrate metabolism in heart failure: from pathways to therapeutic targets. Curr Pharm Design 21(25):3654\u20133664","journal-title":"Curr Pharm Design"},{"key":"12333_CR36","doi-asserted-by":"publisher","first-page":"1649179","DOI":"10.3389\/fonc.2025.1649179","volume":"15","author":"F Chen","year":"2025","unstructured":"Chen F, Lyu L, Xing C, Chen Y, Hu S, Wang M, Ai Z (2025) The pivotal role of TGF-\u03b2\/Smad pathway in fibrosis pathogenesis and treatment. Front Oncol 15:1649179","journal-title":"Front Oncol"},{"key":"12333_CR37","doi-asserted-by":"crossref","unstructured":"Sussman MA, V\u00f6lkers M, Fischer K, Bailey B, Cottage CT, Din S (2011) \u2026 McGregor,M. Myocardial AKT: the omnipresent nexus. Physiological reviews 91(3):1023\u20131070","DOI":"10.1152\/physrev.00024.2010"},{"key":"12333_CR38","doi-asserted-by":"publisher","first-page":"579036","DOI":"10.3389\/fcvm.2020.579036","volume":"7","author":"Z Xiao","year":"2020","unstructured":"Xiao Z, Kong B, Yang H, Dai C, Fang J, Qin T, Huang H (2020) Key player in cardiac hypertrophy, emphasizing the role of toll-like receptor 4. Front Cardiovasc Med 7:579036","journal-title":"Front Cardiovasc Med"},{"key":"12333_CR39","doi-asserted-by":"crossref","unstructured":"Velusamy P, Mohan T, Ravi DB, Kishore Kumar SN, Srinivasan A, Chakrapani LN, Singh A (2020) Saradhadevi Varadharaj, and Periandavan Kalaiselvi. Targeting the Nrf2\/ARE Signaling Pathway to Mitigate Isoproterenol-Induced Cardiac Hypertrophy: Plausible Role of Hesperetin in Redox Homeostasis. Oxidative Medicine and Cellular Longevity no. 1 (2020):9568278","DOI":"10.1155\/2020\/9568278"},{"key":"12333_CR40","doi-asserted-by":"publisher","first-page":"823935","DOI":"10.3389\/fimmu.2021.823935","volume":"12","author":"Q Li","year":"2022","unstructured":"Li Q, Deng Y, Liu L, Zhang C, Cai Y, Zhang T, Han M, Xu G (2022) Sympathetic denervation ameliorates renal fibrosis via inhibition of cellular senescence. Front Immunol 12:823935","journal-title":"Front Immunol"},{"key":"12333_CR41","doi-asserted-by":"crossref","unstructured":"Zheng H, Yan P, Liu P, Yan C, Zhao M, Wang Z, Zheng X, Huajun W, Zhang R, Lee LP, Teoh SH (2025) Ultrasound-activated piezoelectric scaffolds target dual Ca2+\/NF-\u03baB signaling pathways to orchestrate immunomodulation and osteogenesis for accelerated bone regeneration. Mater Today Bio, (35) p.102299","DOI":"10.1016\/j.mtbio.2025.102299"},{"issue":"12","key":"12333_CR42","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3390\/cells12121667","volume":"12","author":"P Lu","year":"2023","unstructured":"Lu P, Zhang D, Ding F, Ma J, Xiang YK, Zhao M (2023) Silencing of circCacna1c inhibits ISO-induced cardiac hypertrophy through miR-29b-2-5p\/NFATc1 axis. Cells 12(12):1667","journal-title":"Cells"},{"issue":"1","key":"12333_CR43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1172\/JCI93557","volume":"128","author":"J Herrera","year":"2018","unstructured":"Herrera J, Henke CA, Bitterman PB (2018) Extracellular matrix as a driver of progressive fibrosis. J Clin Investig 128(1):45\u201353","journal-title":"J Clin Investig"},{"issue":"1","key":"12333_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s44324-025-00063-4","volume":"3","author":"AE Mayorca-Guiliani","year":"2025","unstructured":"Mayorca-Guiliani AE, Leeming DJ, Henriksen K, Mortensen JH, Nielsen SH, Anstee QM, Sanyal AJ, Karsdal MA, Schuppan D (2025) ECM formation and degradation during fibrosis, repair, and regeneration. npj Metabolic Health Disease 3(1):25","journal-title":"npj Metabolic Health Disease"},{"issue":"7","key":"12333_CR45","doi-asserted-by":"publisher","first-page":"845","DOI":"10.7150\/ijbs.11921","volume":"11","author":"H Shi","year":"2015","unstructured":"Shi H, Cheng Y, Ye J, Cai P, Zhang J, Li R, Yang Y, Wang Z, Zhang H, Lin C, Lu X (2015) bFGF promotes the migration of human dermal fibroblasts under diabetic conditions through reactive oxygen species production via the PI3K\/Akt-Rac1-JNK pathways. Int J Biol Sci 11(7):845","journal-title":"Int J Biol Sci"},{"issue":"15","key":"12333_CR46","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.3390\/nu16152399","volume":"16","author":"P Bontempo","year":"2024","unstructured":"Bontempo P, Capasso L, De Masi L, Nebbioso A, Rigano D (2024) Therapeutic potential of natural compounds acting through epigenetic mechanisms in cardiovascular diseases: Current findings and future directions. Nutrients 16(15):2399","journal-title":"Nutrients"},{"issue":"35","key":"12333_CR47","doi-asserted-by":"publisher","first-page":"2202169","DOI":"10.1002\/adma.202202169","volume":"34","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Dalan R, Hu Z, Wang JW, Chew NW, Poh KK, Chen X (2022) Reactive oxygen species scavenging nanomedicine for the treatment of ischemic heart disease. Adv Mater 34(35):2202169","journal-title":"Adv Mater"},{"issue":"6","key":"12333_CR48","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/nu15061340","volume":"15","author":"Y Li","year":"2023","unstructured":"Li Y, He B, Zhang C, He Y, Xia T, Zeng C (2023) Naringenin attenuates isoprenaline-induced cardiac hypertrophy by suppressing oxidative stress through the AMPK\/NOX2\/MAPK signaling pathway. Nutrients 15(6):1340","journal-title":"Nutrients"},{"issue":"2","key":"12333_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/01913123.2023.2175944","volume":"47","author":"SH Elsayed","year":"2023","unstructured":"Elsayed SH, Fares NH, Elsharkawy SH, Mahmoud YI (2023) Flaxseed lignans alleviates isoproterenol-induced cardiac hypertrophy by regulating myocardial remodeling and oxidative stress. Ultrastruct Pathol 47(2):122\u2013129","journal-title":"Ultrastruct Pathol"},{"issue":"2","key":"12333_CR50","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3390\/ijms21020682","volume":"21","author":"F Liu","year":"2020","unstructured":"Liu F, Su H, Liu B, Mei Y, Ke Q, Sun X, Tan W (2020) STVNa attenuates isoproterenol-induced cardiac hypertrophy response through the HDAC4 and Prdx2\/ROS\/Trx1 pathways. Int J Mol Sci 21(2):682","journal-title":"Int J Mol Sci"},{"issue":"20","key":"12333_CR51","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3390\/cells13201674","volume":"13","author":"W Parichatikanond","year":"2024","unstructured":"Parichatikanond W, Duangrat R, Kurose H, Mangmool S (2024) Regulation of \u03b2-adrenergic receptors in the heart: a review on emerging therapeutic strategies for heart failure. Cells 13(20):1674","journal-title":"Cells"},{"issue":"24","key":"12333_CR52","doi-asserted-by":"publisher","first-page":"17270","DOI":"10.3390\/ijms242417270","volume":"24","author":"AS Alonazi","year":"2023","unstructured":"Alonazi AS, Dayel B, Albuaijan AF, Osfur DAB, Hakami AS, Alzayed FM, Alhosaini SS, K. A (2023) Cardioprotective effects of the GRK2 inhibitor paroxetine on isoproterenol-induced cardiac remodeling by modulating NF-\u03baB mediated prohypertrophic and profibrotic gene expression. Int J Mol Sci 24(24):17270","journal-title":"Int J Mol Sci"},{"issue":"7293","key":"12333_CR53","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/nature08991","volume":"464","author":"M Iwabu","year":"2010","unstructured":"Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, Kadowaki T (2010) Adiponectin and AdipoR1 regulate PGC-1\u03b1 and mitochondria by Ca2\u2009+\u2009and AMPK\/SIRT1. Nature 464(7293):1313\u20131319","journal-title":"Nature"},{"issue":"7","key":"12333_CR54","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00109-019-01790-0","volume":"97","author":"GK Adzika","year":"2019","unstructured":"Adzika GK, Machuki JOA, Shang W, Hou H, Ma T, Wu L, Sun H (2019) Pathological cardiac hypertrophy: the synergy of adenylyl cyclases inhibition in cardiac and immune cells during chronic catecholamine stress. J Mol Med 97(7):897\u2013907","journal-title":"J Mol Med"},{"issue":"6","key":"12333_CR55","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.3390\/ijms26062703","volume":"26","author":"D Rasooly","year":"2025","unstructured":"Rasooly D, Pereira AC, Joseph J (2025) Drug discovery and development for heart failure using multi-omics approaches. Int J Mol Sci 26(6):2703","journal-title":"Int J Mol Sci"},{"key":"12333_CR56","doi-asserted-by":"crossref","unstructured":"Sadiq S, Charchar FJ, Sanigorski A, Crowley T, Bookun HR, McClure DN (2025) MicroRNA mediated regulation in early-onset cardiac hypertrophy: Insights from the hypertrophic heart rat model. PLoS ONE, 20(12), e0338909","DOI":"10.1371\/journal.pone.0338909"},{"issue":"11","key":"12333_CR57","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/acer.14471","volume":"44","author":"R Liu","year":"2020","unstructured":"Liu R, Sun F, Forghani P, Armand LC, Rampoldi A, Li D, Xu C (2020) Proteomic profiling reveals roles of stress response, Ca2\u2009+\u2009transient dysregulation, and novel signaling pathways in alcohol-induced cardiotoxicity. Alcoholism: Clin Experimental Res 44(11):2187\u20132199","journal-title":"Alcoholism: Clin Experimental Res"},{"issue":"2","key":"12333_CR58","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/j.2040-4603.2015.tb00624.x","volume":"5","author":"A Takawale","year":"2015","unstructured":"Takawale A, Sakamuri SS, Kassiri Z (2015) Extracellular matrix communication and turnover in cardiac physiology and pathology. Compr Physiol 5(2):687\u2013719","journal-title":"Compr Physiol"},{"issue":"19","key":"12333_CR59","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.3390\/ijms21197412","volume":"21","author":"R Romero-Becerra","year":"2020","unstructured":"Romero-Becerra R, Santamans AM, Folgueira C, Sabio G (2020) p38 MAPK pathway in the heart: new insights in health and disease. Int J Mol Sci 21(19):7412","journal-title":"Int J Mol Sci"},{"issue":"4","key":"12333_CR60","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/jcdd10040166","volume":"10","author":"S Kawaguchi","year":"2023","unstructured":"Kawaguchi S, Moukette B, Hayasaka T, Haskell AK, Mah J, Sep\u00falveda MN, Kim IM (2023) Noncoding RNAs as key regulators for cardiac development and cardiovascular diseases. J Cardiovasc Dev disease 10(4):166","journal-title":"J Cardiovasc Dev disease"},{"issue":"5","key":"12333_CR61","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.3390\/ijms24054692","volume":"24","author":"M Stastna","year":"2023","unstructured":"Stastna M (2023) Proteomics as a tool for the study of mitochondrial proteome, its dysfunctionality and pathological consequences in cardiovascular diseases. Int J Mol Sci 24(5):4692. JavaScript: void (0)","journal-title":"Int J Mol Sci"},{"issue":"19","key":"12333_CR62","doi-asserted-by":"publisher","first-page":"10579","DOI":"10.3390\/ijms221910579","volume":"22","author":"AH Chaanine","year":"2021","unstructured":"Chaanine AH (2021) Metabolic remodeling and implicated calcium and signal transduction pathways in the pathogenesis of heart failure. Int J Mol Sci 22(19):10579","journal-title":"Int J Mol Sci"},{"issue":"5","key":"12333_CR63","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/antiox14050557","volume":"14","author":"S Zhang","year":"2025","unstructured":"Zhang S, Li T, Sun S, Jiang Y, Sun Y, Meng Y (2025) The key role and mechanism of oxidative stress in hypertrophic cardiomyopathy: a systematic exploration based on multi-omics analysis and experimental validation. Antioxidants 14(5):557","journal-title":"Antioxidants"},{"key":"12333_CR64","doi-asserted-by":"publisher","first-page":"659666","DOI":"10.3389\/fcell.2021.659666","volume":"9","author":"X Liu","year":"2021","unstructured":"Liu X, Shi GP, Guo J (2021) Innate immune cells in pressure overload-induced cardiac hypertrophy and remodeling. Front cell Dev biology 9:659666","journal-title":"Front cell Dev biology"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12333-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:02:40Z","timestamp":1784124160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12333-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12333"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12333-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1170"}}